AKTX

7.1807.00%
AG

Abizer Gaslightwala

CEO, President & Director

Mr. Abizer Gaslightwala has been President & CEO of Akari Therapeutics Plc since April 21, 2025 and served as its Independent Director. He is Director of Akari Therapeutics Plc from December 16, 2024. Mr. Gaslightwala is a well-established biotechnology /pharmaceutical industry leader with a demonstrated track record of success in the development and commercialization of novel medicines across a range of companies and therapeutic areas. Mr. Gaslightwala serves as the Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he has full responsibility for a portfolio of products spanning both solid and hematological malignancies. These brands include ZIIHERA for HER2 cancers, ZEPZELCA for small cell lung cancer and RYLAZE, DEFITELIO and VYXEOS for a range of hematological malignancies. Prior to his current position at Jazz Pharmaceuticals, Mr. Gaslightwala has led and driven growth in several leadership roles at Amgen, Pfizer and Johnson & Johnson across multiple brands including Kyprolis, Vectibix, Neulasta, XGEVAf, Repatha and ELIQUIS. His experience spans business unit leadership, brand marketing, sales leadership, commercial pipeline planning, advanced analytics and insights and business development. Mr. Gaslightwala also helped lead R&D strategic planning within the autoimmune/inflammation portfolio at Johnson & Johnson, as well as lead commercial planning for Remicade and several novel pipeline molecules focused on rheumatoid arthritis, inflammatory bowel disease, psoriasis and atopic dermatitis. Additionally, Mr. Gaslightwala advised several life science companies through his time at the Boston Consulting Group (BCG). Mr. Gaslightwala holds a BS in Chemical Engineering from Cornell University and an MBA from the Sloan School of Management and a MS in Chemical Engineering from Massachusetts Institute of Technology.

Positions